A detailed history of Decatur Capital Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Decatur Capital Management, Inc. holds 8,680 shares of VRTX stock, worth $4.12 Million. This represents 1.97% of its overall portfolio holdings.

Number of Shares
8,680
Previous 8,768 1.0%
Holding current value
$4.12 Million
Previous $3.57 Million 1.71%
% of portfolio
1.97%
Previous 2.14%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $35,876 - $39,255
-88 Reduced 1.0%
8,680 $3.63 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $953,540 - $1.14 Million
2,780 Added 46.43%
8,768 $3.57 Million
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $22,009 - $24,633
-70 Reduced 1.16%
5,988 $2.11 Million
Q1 2023

May 09, 2023

SELL
$283.23 - $323.1 $275,866 - $314,699
-974 Reduced 13.85%
6,058 $1.91 Million
Q4 2022

Jan 26, 2023

BUY
$285.76 - $321.48 $2.01 Million - $2.26 Million
7,032 New
7,032 $2.03 Million
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $1.97 Million - $2.32 Million
-10,495 Closed
0 $0
Q1 2021

May 06, 2021

SELL
$207.02 - $241.31 $1.96 Million - $2.29 Million
-9,473 Reduced 47.44%
10,495 $2.26 Million
Q4 2020

Jan 28, 2021

SELL
$207.01 - $276.09 $87,979 - $117,338
-425 Reduced 2.08%
19,968 $4.72 Million
Q3 2020

Nov 03, 2020

BUY
$255.65 - $303.1 $988,087 - $1.17 Million
3,865 Added 23.38%
20,393 $5.55 Million
Q2 2020

Aug 04, 2020

BUY
$225.48 - $295.8 $3.73 Million - $4.89 Million
16,528 New
16,528 $4.8 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Decatur Capital Management, Inc. Portfolio

Follow Decatur Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Decatur Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Decatur Capital Management, Inc. with notifications on news.